Vaccination Deep Into a Pandemic Wave

Potential Mechanisms for a “Third Wave” and the Impact of Vaccination


      In December 2009, when the H1N1 influenza pandemic appeared to be subsiding, public health officials and unvaccinated individuals faced the question of whether continued H1N1 immunization was still worthwhile.


      To delineate what combinations of possible mechanisms could generate a third pandemic wave and then explore whether vaccinating the population at different rates and times would mitigate the wave.


      As part of ongoing work with the Office of the Assistant Secretary for Preparedness and Response at the USDHHS during the H1N1 influenza pandemic, the University of Pittsburgh Models of Infectious Disease Agent Study team employed an agent-based computer simulation model of the Washington DC metropolitan region to delineate what mechanisms could generate a “third pandemic wave” and explored whether vaccinating the population at different rates and times would mitigate the wave. This model included explicit representations of the region's individuals, school systems, workplaces/commutes, households, and communities.


      Three mechanisms were identified that could cause a third pandemic wave; substantially increased viral transmissibility from seasonal forcing (changing influenza transmission with changing environmental conditions, i.e., seasons) and progressive viral adaptation; an immune escape variant; and changes in social mixing from holiday school closures. Implementing vaccination for these mechanisms, even during the down-slope of the fall epidemic wave, significantly mitigated the third wave. Scenarios showed the gains from initiating vaccination earlier, increasing the speed of vaccination, and prioritizing population subgroups based on Advisory Committee on Immunization Practices recommendations.


      Additional waves in an epidemic can be mitigated by vaccination even when an epidemic appears to be waning.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • CDC
        Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage—U.S., October–December 2009.
        MMWR Morb Mortal Wkly Rep. 2010; 59: 1-5
        • CDC
        Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel—U.S., August 2009–January 2010.
        MMWR Morb Mortal Wkly Rep. 2010; 59: 357-362
        • Henderson D.A.
        • Courtney B.
        • Inglesby T.V.
        • Toner E.
        • Nuzzo J.B.
        Public health and medical responses to the 1957–58 influenza pandemic.
        Biosecur Bioterror. 2009; 7: 265-273
        • Rios-Doria D.
        • Chowell G.
        Qualitative analysis of the level of cross-protection between epidemic waves of the 1918–1919 influenza pandemic.
        J Theor Biol. 2009; 261: 584-592
        • Kilbourne E.D.
        Influenza pandemics of the 20th century.
        Emerg Infect Dis. 2006; 12: 9-14
        • Miller M.A.
        • Viboud C.
        • Balinska M.
        • Simonsen L.
        The signature features of influenza pandemics—implications for policy.
        N Engl J Med. 2009; 360: 2595-2598
        • Shi P.
        • Keskinocak P.
        • Swann J.L.
        • Lee B.Y.
        Modelling seasonality and viral mutation to predict the course of an influenza pandemic.
        Epidemiol Infect. 2010; 138: 1472-1481
        • Ferguson N.M.
        • Cummings D.A.
        • Fraser C.
        • Cajka J.C.
        • Cooley P.C.
        • Burke D.S.
        Strategies for mitigating an influenza pandemic.
        Nature. 2006; 442: 448-452
        • Halloran M.E.
        • Ferguson N.M.
        • Eubank S.
        • et al.
        Modeling targeted layered containment of an influenza pandemic in the U.S..
        Proc Natl Acad Sci U S A. 2008; 105: 4639-4644
        • National Center for Immunization and Respiratory Diseases C
        Use of influenza A (H1N1) 2009 monovalent vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
        MMWR Recomm Rep. 2009; 58: 1-8
        • Lee B.Y.
        • Brown S.T.
        • Cooley P.C.
        A computer simulation of employee vaccination to mitigate an influenza epidemic.
        Am J Prev Med. 2010; 38: 247-257
        • Wheaton W.D.
        • Cajka J.C.
        • Chasteen B.M.
        • et al.
        Synthesized population databases: a U.S. geospatial database for agent-based models.
        Methods Rep RTI Press. 2009; : 905
        • Beckman R.J.
        • Baggerly K.
        • McKay M.
        Creating synthetic baseline populations.
        Policy Pract. 1996; 30: 415-429
        • Eubank S.
        • Guclu H.
        • Kumar V.S.
        Modelling disease outbreaks in realistic urban social networks.
        Nature. 2004; 429: 180-184
        • Ferguson N.M.
        • Cummings D.A.
        • Cauchemez S.
        Strategies for containing an emerging influenza pandemic in Southeast Asia.
        Nature. 2005; 437: 209-214
        • Germann T.C.
        • Kadau K.
        • Longini Jr, I.M.
        • Macken C.A.
        Mitigation strategies for pandemic influenza in the U.S..
        Proc Natl Acad Sci U S A. 2006; 103: 5935-5940
        • Longini Jr, I.M.
        • Halloran M.E.
        • Nizam A.
        • Yang Y.
        Containing pandemic influenza with antiviral agents.
        Am J Epidemiol. 2004; 159: 623-633
        • Longini Jr, I.M.
        • Nizam A.
        • Xu S.
        • et al.
        Containing pandemic influenza at the source.
        Science. 2005; 309: 1083-1087
        • Lee B.Y.
        • Brown S.T.
        • Cooley P.
        Simulating school closure strategies to mitigate an influenza epidemic.
        J Public Health Manag Pract. 2010; 16: 252-261
        • Ling L.M.
        • Chow A.L.
        • Lye D.C.
        Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.
        Clin Infect Dis. 2010; 50: 963-969
        • Rothberg M.B.
        • Rose D.N.
        Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
        Am J Med. 2005; 118: 68-77
        • Lee B.Y.
        • Tai J.H.
        • Bailey R.R.
        • Smith K.J.
        The timing of influenza vaccination for older adults (65 years and older).
        Vaccine. 2009; 27: 7110-7115
        • Beigi R.H.
        • Wiringa A.E.
        • Bailey R.R.
        • Assi T.M.
        • Lee B.Y.
        Economic value of seasonal and pandemic influenza vaccination during pregnancy.
        Clin Infect Dis. 2009; 49: 1784-1792
        • Bureau of Labor Statistics
        American time use survey—2008 results.
        U.S. Department of Labor, Washington DC2009
        • Lee B.Y.
        • Tai J.H.
        • Bailey R.R.
        • Smith K.J.
        • Nowalk A.J.
        Economics of influenza vaccine administration timing for children.
        Am J Manag Care. 2010; 16: e75-e85
        • Anderson R.M.
        • May R.M.
        Infectious diseases of humans.
        Oxford University Press, New York1992
        • Casagrandi R.
        • Bolzoni L.
        • Levin S.A.
        • Andreasen V.
        The SIRC model and influenza A.
        Math Biosci. 2006; 200: 152-169
        • National Institute of Allergy and Infectious Disease
        Early results: in children, 2009 H1N1 influenza vaccine works like seasonal flu vaccine.
        USDHHS, NIH, Bethesda MD2009
        • National Institute of Allergy and Infectious Disease
        Updated results: in youngest children, a second dose of 2009 H1N1 influenza vaccine elicits robust immune response.
        USDHHS, NIH, Bethesda MD2009
        • CDC
        Recommendations for vaccine against 2009 H1N1 influenza virus.
        • WHO
        Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus.
        Wkly Epidemiol Rec. 2009; 84: 481-484
        • Olson D.R.
        • Simonsen L.
        • Edelson P.J.
        • Morse S.S.
        Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City.
        Proc Natl Acad Sci U S A. 2005; 102: 11059-11063
        • Bridges C.B.
        • Katz J.M.
        • Levandowski R.A.
        • Cox N.J.
        Inactivated influenza vaccines.
        in: Plotkin S. Orenstein W. Offit P. Vaccines. 5th ed. Saunders Elsevier, Philadelphia2008: 259-290
        • Murray R.
        Production and testing in the USA of influenza virus vaccine made from the Hong Kong variant in 1968–69.
        Bull WHO. 1969; 41: 495-496
        • Martin A.E.
        A serological investigation into the epidemiology of influenza with particular reference to sporadic cases.
        J Hyg (Lond). 1940; 40: 104-114
        • Shaman J.
        • Pitzer V.E.
        • Viboud C.
        • Grenfell B.T.
        • Lipsitch M.
        Absolute humidity and the seasonal onset of influenza in the continental U.S..
        PLoS Biol. 2010; 8 (e1000316)
        • Hope-Simpson R.E.
        The role of season in the epidemiology of influenza.
        J Hyg (Lond). 1981; 86: 35-47
        • Shen J.
        • Ma J.
        • Wang Q.
        Evolutionary trends of A(H1N1) influenza virus hemagglutinin since 1918.
        PLoS One. 2009; 4 (e7789)
        • Nelson M.I.
        • Viboud C.
        • Simonsen L.
        Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918.
        PLoS Pathog. 2008; 4 (e1000012)
        • Lindstrom S.E.
        • Cox N.J.
        • Klimov A.
        Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957–1972: evidence for genetic divergence and multiple reassortment events.
        Virology. 2004; 328: 101-119
        • Nakao H.
        • N K.
        • Nakajima S.
        Location on the evolutionary trees of the non-structural protein (NS) and neuraminidase (NA) genes of late human influenza A (H2N2) viruses: parental viruses of the NS and NA genes of Hong Kong influenza A (H3N2) viruses.
        J Gen Virol. 1993; 74: 1667-1672
        • Shinde V.
        • Bridges C.B.
        • Uyeki T.M.
        Triple-reassortant swine influenza A (H1) in humans in the U.S., 2005–2009.
        N Engl J Med. 2009; 360: 2616-2625
        • Webster R.G.
        • Bean W.J.
        • Gorman O.T.
        • Chambers T.M.
        • Kawaoka Y.
        Evolution and ecology of influenza A viruses.
        Microbiol Rev. 1992; 56: 152-179